Hummingbird Bioscience, focused on precision antibody therapeutics, announced that it has raised $19 million in a Series B funding round co-anchored by Mirae Asset Venture Investment and GNTech Venture Capital.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
